Cytokinetics (CYTK) Other Non-Current Assets (2010 - 2026)
Cytokinetics (CYTK) posted quarterly Other Non-Current Assets of $18.5 million for Q1 2026, up 45.45% year-over-year from $12.7 million in Q1 2025, and up 6.5% quarter-over-quarter from $17.3 million in Q4 2025.
Cytokinetics (CYTK) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Other Non-Current Assets for 17 consecutive years, with $18.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 45.45% year-over-year to $18.5 million; the TTM figure through Mar 2026 stood at $18.5 million (up 45.45% YoY), while the FY2025 annual figure was $17.3 million, up 125.06% from the prior year.
- Other Non-Current Assets grew to $18.5 million in Q1 2026 per CYTK's latest filing, from $17.3 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $18.5 million in Q1 2026 and bottomed at $7.3 million in Q1 2022.
- Historically, Other Non-Current Assets has averaged $10.4 million across 5 years, with a median of $8.1 million in 2023.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets slipped 17.49% — and 2025, when it jumped 125.06%.
- Cytokinetics' Other Non-Current Assets stood at $9.7 million in 2022, then fell by 17.49% to $8.0 million in 2023, then slipped by 3.64% to $7.7 million in 2024, then soared by 125.06% to $17.3 million in 2025, then grew by 6.5% to $18.5 million in 2026.
- Business Quant data shows CYTK's Other Non-Current Assets at $18.5 million in Q1 2026, $17.3 million in Q4 2025, and $16.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn | 19.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.41 Mn |
| Mar 31, 2026 | 18.47 Mn |
| Dec 31, 2025 | 17.34 Mn |
| Sep 30, 2025 | 16.81 Mn |
| Jun 30, 2025 | 14.55 Mn |
| Mar 31, 2025 | 12.70 Mn |
| Dec 31, 2024 | 7.71 Mn |
| Sep 30, 2024 | 7.73 Mn |
| Jun 30, 2024 | 7.68 Mn |
| Mar 31, 2024 | 7.81 Mn |
| Dec 31, 2023 | 8.00 Mn |
| Sep 30, 2023 | 8.19 Mn |
| Jun 30, 2023 | 8.34 Mn |
| Mar 31, 2023 | 8.12 Mn |
| Dec 31, 2022 | 9.69 Mn |
| Sep 30, 2022 | 7.76 Mn |
| Jun 30, 2022 | 8.05 Mn |
| Mar 31, 2022 | 7.26 Mn |
| Dec 31, 2021 | 7.19 Mn |
| Sep 30, 2021 | 6.68 Mn |